Abstract
Regulatory changes in the United States and Europe have stimulated major pediatric clinical trials of over 15 different antihypertensive agents over the last two decades. With increased pediatric hypertension trial experience, trial designs have been refined, and we now better understand factors associated with trial success or failure. Appropriate dose range, weight-based dosing, use of a liquid formulation, and use of appropriate blood pressure endpoints are all factors that have been associated with improved trial success. These lessons learned and important modifications in trial design templates are reflected in the United States Food and Drug Administration Written Request criteria. The Written Request provides valuable information that can be used to optimally design future clinical trials of antihypertensive agents as well as other therapeutic agents for use in children.
This is a preview of subscription content, log in via an institution to check access.
References
American Academy of Pediatrics, Committee on Drugs (1977) Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 60:91–101
Batisky DL, Sorof JM, Sugg J et al (2007) Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 150:134–139, 139 e1
Benjamin DK Jr, Smith PB, Murphy MD et al (2006) Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 296:1266–1273
Benjamin DK Jr, Smith PB, Jadhav P et al (2008) Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 51:834–840
Blowey DL (2012) Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens (Greenwich) 14:383–387
Blumer JL, Daniels SR, Dreyer WJ et al (2003) Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. J Clin Pharmacol 43:128–132
European Medicines Agency (2016a) Paediatric investigation plans. Accessed at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000293.jsp&mid=WC0b01ac0580025b91. 25 July 2016
European Medicines Agency (2016b) Paediatric-use marketing authorisations. Accessed at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000413.jsp&mid=WC0b01ac0580925c40. 18 Oct 2016
Ferguson MA, Flynn JT (2014) Treatment of pediatric hypertension: lessons learned from recent clinical trials. Curr Cardiovasc Risk Rep 8:399
Flynn JT (2003) Ethics of placebo use in pediatric clinical trials: the case of antihypertensive drug studies. Hypertension 42:865–869
Flynn JT, Alderman MH (2005) Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol 20:961–966
Flynn JT, Daniels SR (2006) Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 149:746–754
Flynn JT, Newburger JW, Daniels SR et al (2004) A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 145:353–359
Flynn JT, Meyers KE, Neto JP et al (2008) Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension 52:222–228
Flynn JT, Pierce CB, Miller ER 3rd, Charleston J, Samuels JA, Kupferman J, Furth SL, Warady BA (2012) Chronic kidney disease in children study Group. Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. J Pediatr 160(3):434–440
Full text of Best Pharmaceuticals for Children Act (2002). Accessed at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148011.htm. 25 July 2016
Full text of European Parliament regulation no. 1901/2006 on medicinal products for paediatric use (2006). Accessed online at: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. 25 July 2016
Full text of Food and Drug Administration Amendments Act (2007). Accessed at: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm. 25 July 2016
Full text of Food and Drug Administration Modernization Act (1997). Accessed at: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticAct FDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. 25 July 2016
Full text of Food and Drug Administration Safety and Innovation Act (2012). Accessed at: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm20027187.htm. 16 July 2016
Full text of Pediatric Research Equity Act (2003). Accessed at: http://www.gpo.gov/fdsys/pkg/PLAW-108publ155/html/PLAW-108publ155.htm. 16 July 2016
Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Committee on Drugs, American Academy of Pediatrics (1995). Pediatrics 95:286–294
Hammer GB, Lewandowski A, Drover DR et al (2015) Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. Pediatr Crit Care Med 16:397–403
Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R (2010) A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 55:1323–1330
Li JS, Berezny K, Kilaru R et al (2004) Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension 44:289–293
Li JS, Eisenstein EL, Grabowski HG et al (2007) Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297:480–488
Li JS, Flynn JT, Portman R et al (2010) The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 157:282–287
Meyers KE, Lieberman K, Solar-Yohay S, Han G, Shi V (2011) The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients. J Clin Hypertens (Greenwich) 13:758–766
Pasquali SK, Sanders SP, Li JS (2002) Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am Heart J 144:608–614
Rodriguez W, Selen A, Avant D et al (2008) Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121:530–539
Regulation (EC) No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 4 Jan 2016
Sakarcan A, Tenney F, Wilson JT et al (2001) The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 41:742–749
Schaefer F, van de Walle J, Zurowska A et al (2010) Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens 28:1083–1090
Schaefer F, Litwin M, Zachwieja J et al (2011) Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 29:2484–2490
Shahinfar S, Cano F, Soffer BA et al (2005) A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 18:183–190
Skirton H, Chamberlain W, Lawson C, Ryan H, Young E (2011) A systematic review of variability and reliability of manual and automated blood pressure readings. J Clin Nurs 20:602–614
Smith PB, Li JS, Murphy MD, Califf RM, Benjamin DK Jr (2008) Safety of placebo controls in pediatric hypertension trials. Hypertension 51:829–833
Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S (2003) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 16:795–800
Sorof JM, Cargo P, Graepel J et al (2002a) Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 17:345–350
Sorof JM, Poffenbarger T, Franco K, Bernard L, Portman RJ (2002b) Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr 140:660–666
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents (2004). Pediatrics 114:555–576
Trachtman H, Frank R, Mahan JD et al (2003) Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 18:548–553
Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J (2008) Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 10:743–750
U.S. Food and Drug Administration (2016a) New pediatric labeling information database. Accessed online at: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. 25 July 2016
U.S. Food and Drug Administration (2016b) Pediatric product development. Accessed online at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm. 18 Oct 2016
Wells T, Frame V, Soffer B et al (2002) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 42:870–880
Wells TG, Portman R, Norman P, Haertter S, Davidai G, Fei W (2010) Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clin Pediatr (Phila) 49:938–946
Wells T, Blumer J, Meyers KE et al (2011) Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) 13:357–365
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this entry
Cite this entry
Hill, K.D., Torok, R.D., Portman, R.J., Li, J.S. (2016). Changes in Drug Development Regulations and Their Impact on Clinical Trials. In: Flynn, J., Ingelfinger, J., Redwine, K. (eds) Pediatric Hypertension. Springer, Cham. https://doi.org/10.1007/978-3-319-31420-4_38-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-31420-4_38-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Online ISBN: 978-3-319-31420-4
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Changes in Drug Development Regulations and Their Impact on Clinical Trials- Published:
- 21 May 2022
DOI: https://doi.org/10.1007/978-3-319-31420-4_38-2
-
Original
Changes in Drug Development Regulations and Their Impact on Clinical Trials- Published:
- 17 December 2016
DOI: https://doi.org/10.1007/978-3-319-31420-4_38-1